---
title: "Corneal Surgery"
order: 4
category: "Ophthalmology"
---

# Corneal Surgery and Keratoplasty

## Overview

Corneal surgery encompasses procedures to restore corneal clarity, structure, and refractive function. Keratoplasty (corneal transplantation) replaces diseased cornea with healthy donor tissue, representing one of the most successful transplant procedures worldwide. Modern corneal surgery has evolved from full-thickness penetrating keratoplasty (PK) to selective layer transplantation (endothelial keratoplasty, anterior lamellar keratoplasty), reducing rejection risk and improving visual outcomes. Additional procedures include refractive surgery (LASIK, PRK), cross-linking for keratoconus, and pterygium excision.

## Corneal Anatomy and Physiology

### Layers (Anterior to Posterior)

**1. Epithelium** (50 μm):
- Stratified squamous, non-keratinized (5-7 cell layers)
- **Regeneration**: Rapid (24-48 hours), from limbal stem cells
- **Function**: Barrier to infection, smooth optical surface
- **Innervation**: Dense (trigeminal CN V1), responsible for blink reflex, tearing

**2. Bowman's Layer** (8-12 μm):
- Acellular, condensed collagen
- **No regeneration** if damaged (scarring results)
- Absent in peripheral cornea

**3. Stroma** (500 μm, 90% of corneal thickness):
- Highly organized collagen lamellae (parallel arrangement → transparency)
- **Keratocytes**: Corneal fibroblasts (maintain collagen, transparency)
- **Hydration**: 78% water (deturgescence critical for clarity)

**4. Descemet's Membrane** (10-12 μm):
- Basement membrane of endothelium
- Elastic, resistant to enzymatic digestion
- Regenerates if endothelium intact

**5. Endothelium** (4-6 μm single layer):
- **Critical**: Pumps fluid out of stroma (maintains deturgescence, transparency)
- **Na-K ATPase pumps**: Active transport
- **NO regeneration** in adults (cells enlarge to cover defects)
- **Cell density**: 3000-4000 cells/mm² at birth, 2500 cells/mm² in adults
- **Failure threshold**: <500 cells/mm² (corneal edema, loss of clarity)

### Corneal Clarity

**Requirements**:
- Regular collagen architecture (parallel lamellae)
- Relative dehydration (endothelial pump function)
- Avascularity
- Transparency of layers

**Loss of clarity**: Edema (endothelial failure), scarring (trauma, infection), irregularity (keratoconus), infiltration (dystrophies)

### Corneal Dimensions

- **Diameter**: 11-12mm horizontal, 10-11mm vertical
- **Central thickness**: 500-550 μm
- **Refractive power**: ~43 diopters (2/3 of eye's total refractive power)

## Corneal Pathology Requiring Surgery

### Endothelial Dysfunction

**Fuchs' Endothelial Dystrophy**:
- Progressive endothelial cell loss, guttae (excrescences on Descemet's)
- **Symptoms**: Morning vision blur (overnight corneal edema), glare, pain (epithelial bullae)
- **Treatment**: DSEK/DMEK when symptomatic

**Bullous Keratopathy**:
- Endothelial failure (pseudophakic, aphakic, traumatic)
- **Symptoms**: Pain (epithelial bullae rupture), blurred vision
- **Treatment**: DSEK/DMEK

### Stromal Scarring

**Causes**: Infection (bacterial, viral, fungal keratitis), trauma, chemical injury, corneal dystrophies (lattice, granular)
**Treatment**: Penetrating keratoplasty (PK), deep anterior lamellar keratoplasty (DALK) if endothelium healthy

### Keratoconus

**Definition**: Progressive corneal thinning and ectasia (cone-shaped protrusion)
**Pathophysiology**: Collagen cross-link breakdown
**Progression**: Typically in teens-30s, stabilizes 30-40s
**Treatment**:
- **Glasses/contact lenses**: Early (rigid gas permeable lenses best)
- **Corneal cross-linking**: Halt progression
- **Intacs**: Intrastromal ring segments (reshape cornea)
- **Keratoplasty**: Advanced cases (PK or DALK)

### Infectious Keratitis

**Severe scarring** after treatment may require PK

### Corneal Dystrophies

- **Fuchs'** (endothelial)
- **Lattice, granular** (stromal)
- **Map-dot-fingerprint** (epithelial)

## Penetrating Keratoplasty (PK)

### Principle

Full-thickness replacement of central cornea (all 5 layers) with donor cornea

### Indications

- **Fuchs' dystrophy**: Previously most common, now DSEK/DMEK preferred
- **Keratoconus**: Advanced, cannot wear contacts
- **Corneal scarring**: Infection, trauma, chemical injury
- **Corneal dystrophies**: Lattice, granular
- **Failed prior graft**
- **Corneal perforation**: Therapeutic PK (larger graft, not centered on visual axis)

### Donor Tissue

**Eye Banks**: Procure, evaluate, preserve donor corneas
**Selection**:
- **Cell count**: Minimum 2000-2500 cells/mm² (for PK)
- **Serology**: HIV, hepatitis B/C negative
- **Preservation**: Optisol or similar media (14 days), organ culture (4-6 weeks in Europe)

**Contraindications**: Prior intraocular surgery (LASIK acceptable), infection, malignancy, prion disease

### Surgical Technique

**Anesthesia**: Local (retrobulbar or peribulbar) or general

**Steps**:

1. **Trephination of Host Cornea**:
   - Mark center (visual axis)
   - **Trephine**: Circular blade (7.5-9.0mm diameter, typically 7.5-8.0mm)
   - Cut partial thickness, then complete with scissors
   - Avoid entering anterior chamber until controlled (prevent iris prolapse, lens injury)

2. **Preparation of Donor Button**:
   - **Endothelial side up** (protect endothelium)
   - Trephine donor cornea (0.25-0.5mm larger than host - provides better peripheral seal)

3. **Placement of Donor Button**:
   - Place in host bed, ensure centered

4. **Suturing**:
   - **Interrupted sutures** (16 or 24, 10-0 nylon): Adjustable tension, selective removal
   - **Running suture** (16 or 24 bites, 10-0 nylon): Faster, even tension, more astigmatism
   - **Combined**: 8 interrupted + running suture
   - **Tension**: Watertight, avoid excessive tightness (astigmatism)

5. **Anterior Chamber Reformation**: Inflate with balanced salt solution

6. **Check for Leaks**: Test wound (fluorescein dye)

**Intraoperative Challenges**:
- **Iris prolapse**: Return to AC, may need iridectomy
- **Lens injury**: Cataract formation (extract or monitor)
- **Vitreous loss**: Anterior vitrectomy if needed

### Postoperative Management

**Medications**:
- **Topical steroids**: Prednisolone acetate 1%, frequent initially (q1-2h), slow taper over 1 year (prevent rejection)
- **Antibiotics**: First 1-2 weeks
- **Antivirals**: If herpetic keratitis history (prevent recurrence)

**Suture Management**:
- **Remove**: 12-18 months post-op (earlier if vascularized, loose, or causing irritation)
- **Selective removal**: Adjust astigmatism
- **Running suture**: Remove after 1-2 years (all at once or convert to interrupted)

**Refraction**:
- **Unstable** until sutures removed
- **High astigmatism** common (3-8D)
- Correct with glasses, contact lenses, later with laser (LASIK/PRK) or incisional surgery

**Follow-Up**:
- **Frequent** initially (weekly, then monthly)
- **Lifelong** (rejection risk never zero)

### Complications

**Early**:
- **Primary graft failure** (1-5%): Donor endothelium fails immediately (cloudy cornea POD 1)
  - **Cause**: Poor donor tissue, surgical trauma
  - **Treatment**: Repeat transplant
- **Wound leak**: Suture, glue, bandage contact lens
- **Infection**: Bacterial, fungal (rare but devastating)
- **Epithelial defect**: Usually heals within 1 week (delayed if neurotrophic)

**Late**:
- **Rejection** (10-30% at 5 years):
  - **Epithelial rejection**: Least severe, epithelial rejection line
  - **Subepithelial rejection**: Khodadoust line (advancing line of infiltrate)
  - **Endothelial rejection**: MOST SEVERE, keratic precipitates, corneal edema
  - **Presentation**: Decreased vision, redness, photophobia
  - **Treatment**: Intensive topical steroids (q1h), oral steroids (severe), reversal possible if caught early
  - **Irreversible rejection**: Regraft needed
- **Glaucoma**: Secondary (steroid-induced, inflammation, angle damage)
- **Cataract**: Accelerated formation (30-50%)
- **Astigmatism**: High irregular astigmatism common (3-10D)
- **Recurrence of disease**: Herpetic keratitis, dystrophies can recur in graft

### Outcomes

**Graft Survival**:
- **1 year**: 90%
- **5 years**: 70-80%
- **10 years**: 50-60%

**Visual Outcomes**:
- **20/40 or better**: 50-70% (limited by astigmatism, underlying disease)

**Risk Factors for Failure**:
- Vascularized recipient bed (inflammatory diseases)
- Prior failed graft
- Glaucoma
- Peripheral anterior synechiae
- Young age (higher rejection)

## Endothelial Keratoplasty

### Principle

**Selective replacement** of diseased endothelium and Descemet's membrane, preserving healthy stroma and epithelium

**Advantages over PK**:
- Smaller incision (less astigmatism)
- Faster visual recovery
- Stronger eye (less rupture risk)
- Lower rejection risk

### Types

**1. Descemet's Stripping Endothelial Keratoplasty (DSEK)**:
- Replace endothelium + Descemet's + thin posterior stroma (~100-150 μm)

**2. Descemet's Membrane Endothelial Keratoplasty (DMEK)**:
- Replace endothelium + Descemet's only (~10-15 μm)
- **Advantages**: Faster recovery, better visual outcomes, lower rejection
- **Disadvantages**: Technically more challenging (thin tissue difficult to manipulate)

**3. DSAEK**: DSEK with automated lamellar dissection (more uniform thickness)

### Indications

- **Fuchs' endothelial dystrophy** (most common)
- **Pseudophakic/aphakic bullous keratopathy**
- **Failed prior PK** (endothelial failure)
- **Congenital hereditary endothelial dystrophy**

**Requires**: Healthy epithelium, stroma (if scarred, need PK or DALK)

### DMEK Surgical Technique

**Donor Preparation**:
- **Pre-cut tissue**: Most surgeons use pre-cut donor from eye bank
- Descemet's membrane with endothelium stripped from donor stroma (scrolls into tight roll)

**Recipient Preparation**:
1. **Descemetorhexis**: Remove recipient's Descemet's and endothelium (8-9mm diameter)
   - Score with reverse Sinskey hook
   - Peel with forceps

**Graft Insertion**:
1. Small temporal incision (3-4mm)
2. Insert scrolled donor tissue through incision using injector or forceps
3. Graft unfurls in anterior chamber (with viscoelastic or BSS)

**Graft Attachment**:
1. **Air bubble**: Inject air into anterior chamber (pushes graft against posterior stroma)
2. **Patient supine**: 30-60 minutes (allows graft adherence)
3. **Partial air fill**: Leave 20-50% air (prevents pupillary block, IOP spike)

**Postoperative**:
- **Positioning**: Supine as much as possible for 24-48 hours
- **Monitor IOP**: Air can cause elevation or hypotony
- **Re-bubbling**: 15-30% require additional air injection (graft detachment, incomplete adherence)

### Complications

**Intraoperative**:
- **Graft tear/damage**: Handle carefully (DMEK tissue very thin)
- **Upside-down graft**: Donor endothelium must face posteriorly (mark orientation)

**Early Postoperative**:
- **Graft detachment**: Partial (observe) or complete (re-bubble urgently)
- **IOP elevation**: From air bubble
- **Pupillary block**: Air traps aqueous (peripheral iridotomy prevents)

**Late**:
- **Primary graft failure**: 2-5% (donor tissue failure)
- **Rejection**: 5-10% at 5 years (lower than PK - only endothelium transplanted)
- **Secondary graft failure**: Endothelial cell loss over time

### Outcomes

**DMEK**:
- **Visual recovery**: Faster than DSEK/PK (weeks vs. months)
- **Final vision**: 70-80% achieve 20/25 or better (better than PK/DSEK)
- **Rejection**: 5-10% at 5 years (lower than PK)
- **Graft survival**: >90% at 5 years

**DSEK**: Slightly lower visual outcomes (20/30-40) but easier technique, fewer detachments

## Deep Anterior Lamellar Keratoplasty (DALK)

### Principle

Replace anterior stroma (epithelium + Bowman's + stroma) while preserving recipient's Descemet's and endothelium

### Indications

- **Keratoconus** (endothelium healthy)
- **Anterior stromal scarring**: Infection, trauma, dystrophies
- **Avoid endothelial transplantation**: Lower rejection risk (host endothelium retained)

### Surgical Technique

**Big Bubble Technique** (Anwar):
1. **Partial trephination**: 80% depth
2. **Air injection**: Into deep stroma (creates cleavage plane between stroma and Descemet's - "big bubble")
3. **Remove anterior stroma**: Separate stroma from Descemet's, excise
4. **Donor preparation**: Remove Descemet's and endothelium from donor button
5. **Suture donor**: Donor stroma to recipient Descemet's

**Alternative**: Manual dissection if big bubble fails

### Advantages over PK

- **Lower rejection risk**: Endothelium (highest rejection risk) not transplanted
- **Stronger eye**: No full-thickness incision
- **No endothelial cell loss** over time

### Disadvantages

- **Technically challenging**: Learning curve
- **Conversion to PK**: 10-20% if Descemet's perforation
- **Interface haze**: Slight (usually not vision-limiting)

### Outcomes

- **Visual outcomes**: Comparable to PK (20/40 or better in 70-80%)
- **Rejection**: Much lower than PK (no endothelial rejection)
- **Graft survival**: Excellent (>90% at 10 years)

## Corneal Cross-Linking (CXL)

### Principle

**Strengthen corneal collagen** to halt keratoconus progression

### Mechanism

- **Riboflavin** (vitamin B2) + **UVA light** (365nm)
- Photochemical reaction creates covalent bonds between collagen fibrils (cross-links)
- Increases corneal rigidity, halts ectasia progression

### Indications

- **Progressive keratoconus** (documented progression)
- **Post-LASIK ectasia**
- **Pellucid marginal degeneration**

**Not for**: Stable keratoconus, advanced keratoconus with scarring

### Technique (Dresden Protocol)

**Epithelium-Off (Standard)**:
1. Remove corneal epithelium (central 7-9mm)
2. Apply riboflavin 0.1% drops every 2 minutes for 30 minutes
3. UVA irradiation (3mW/cm², 30 minutes)
4. Continue riboflavin during UVA exposure

**Epithelium-On** (Transepithelial):
- Riboflavin with penetration enhancers
- **Advantages**: Less pain, faster healing
- **Disadvantages**: Less riboflavin penetration (potentially less effective)

**Accelerated Protocols**: Higher UVA intensity, shorter time (9-18mW/cm², 3-10 minutes) - same total energy

### Postoperative Care

- **Bandage contact lens**: 3-5 days (re-epithelialization)
- **Topical antibiotics and NSAIDs**
- **Pain**: Moderate for 2-3 days

### Outcomes

- **Halt progression**: 90-95% of cases
- **Improvement**: 50-70% show flattening/reduced astigmatism
- **Vision**: Stable or slight improvement

### Complications

- **Corneal haze**: Temporary (3-6 months), usually resolves
- **Infection**: Rare (bacterial, herpetic keratitis reactivation)
- **Corneal melting**: Very rare (thin corneas)
- **Endothelial damage**: If cornea <400 μm (avoid CXL in very thin corneas)

## Refractive Surgery

### LASIK (Laser-Assisted In Situ Keratomileusis)

**Principle**: Create corneal flap, ablate stroma with excimer laser (reshape cornea), replace flap

**Indications**: Myopia, hyperopia, astigmatism

**Technique**:
1. Create flap (microkeratome or femtosecond laser) - 100-160 μm thick
2. Lift flap
3. Excimer laser ablation of stromal bed (flatten for myopia, steepen for hyperopia)
4. Replace flap (adheres without sutures)

**Advantages**: Rapid visual recovery (hours-days), minimal pain

**Complications**: Flap complications (dislocation, wrinkles), dry eye, infection, ectasia (if too thin residual stromal bed)

### PRK (Photorefractive Keratectomy)

**Principle**: Remove epithelium, ablate anterior stroma directly (no flap)

**Advantages**: No flap complications, suitable for thinner corneas, military/contact sports

**Disadvantages**: Slower visual recovery (days-weeks), more pain, corneal haze (rare)

### Outcomes

- **Emmetropia** (no glasses): 90-95% within ±0.5D of target
- **Safety**: Excellent in properly selected patients
- **Contraindications**: Keratoconus, thin corneas, unstable refraction, autoimmune disease

## Pterygium

### Definition

Fibrovascular growth of conjunctiva onto cornea (typically nasal)

### Etiology

- **UV exposure**: Primary risk factor
- **Dry, dusty climates**

### Indications for Surgery

- **Visual impairment**: Encroachment on visual axis
- **Astigmatism**: Induced by pterygium
- **Cosmesis**: Patient request
- **Irritation**: Chronic inflammation, foreign body sensation

### Surgical Technique

**Excision with Conjunctival Autograft** (preferred):
1. Excise pterygium (bare sclera technique)
2. Harvest conjunctival graft from superior bulbar conjunctiva
3. Suture or glue graft to bare sclera

**Advantages**: Lowest recurrence rate (5-10%)

**Alternative**: Excision with amniotic membrane graft

**Adjuvant**: Mitomycin-C intraoperative application (reduce recurrence, but risk of scleral thinning/perforation)

### Complications

- **Recurrence**: 5-40% (depending on technique)
- **Scarring, conjunctival granuloma**
- **Diplopia**: If extensive excision

## Key Points

- Corneal endothelium critical for transparency (pumps fluid out of stroma); non-regenerative in adults, failure (<500 cells/mm²) causes edema
- Penetrating keratoplasty (PK) full-thickness transplant; endothelial keratoplasty (DSEK/DMEK) selective layer replacement with faster recovery and lower rejection
- DMEK replaces only endothelium + Descemet's (10-15 μm); best visual outcomes (70-80% achieve ≥20/25) but technically challenging with 15-30% re-bubbling rate
- PK graft survival: 90% at 1 year, 70-80% at 5 years; rejection risk 10-30%, treated with intensive topical steroids
- Deep anterior lamellar keratoplasty (DALK) replaces stroma while preserving host endothelium; lower rejection risk than PK, ideal for keratoconus
- Fuchs' endothelial dystrophy most common indication for DSEK/DMEK; progressive endothelial cell loss causes morning blur (overnight corneal edema)
- Corneal cross-linking (riboflavin + UVA light) halts keratoconus progression in 90-95%; creates collagen cross-links to strengthen cornea
- Keratoconus progressive ectasia typically in teens-30s; treat with RGP lenses (early), cross-linking (progressive), keratoplasty (advanced)
- Corneal transplant rejection presents with decreased vision, redness, photophobia; endothelial rejection most severe (requires urgent high-dose steroids)
- LASIK creates flap + excimer laser stromal ablation for refractive correction; PRK no flap (surface ablation), slower recovery but no flap complications
- Pterygium excision with conjunctival autograft has lowest recurrence (5-10%); mitomycin-C adjuvant reduces recurrence but increases complications
- Donor cornea requirements: endothelial cell count ≥2000-2500 cells/mm², serology negative (HIV, hepatitis); preserved in Optisol for 14 days

## References

1. Eye Bank Association of America. Medical Standards (2022)
2. Price MO, et al. Descemet's membrane endothelial keratoplasty: prospective multicenter study of visual and refractive outcomes and endothelial survival. Ophthalmology. 2009;116(12):2361-2368
3. Wollensak G, et al. Riboflavin/ultraviolet-a-induced collagen crosslinking for the treatment of keratoconus. Am J Ophthalmol. 2003;135(5):620-627
4. Williams KA, et al. How effective is penetrating corneal transplantation? Factors influencing long-term outcome. Transplantation. 2006;81(6):896-901
5. Tan DT, et al. Randomized clinical trial of a new dexamethasone delivery system (Surodex) for treatment of post-cataract surgery inflammation. Ophthalmology. 1999;106(2):223-231
